Skip to main content
Top
Published in: BMC Complementary Medicine and Therapies 1/2016

Open Access 01-12-2016 | Research article

Ethanolic extract of Descurainia sophia seeds sensitizes A549 human lung cancer cells to TRAIL cytotoxicity by upregulating death receptors

Authors: Jong-Shik Park, Chae Jun Lim, Ok-Sun Bang, No Soo Kim

Published in: BMC Complementary Medicine and Therapies | Issue 1/2016

Login to get access

Abstract

Background

Our previous genome-wide gene expression analysis revealed that tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptors 4 (DR4) and 5 (DR5) are markedly upregulated by the ethanolic extract of D. sohia seeds (EEDS) in A549 TRAIL-refractory cancer cells. In the present study, we investigated whether the EEDS-mediated upregulation of TRAIL death receptors was associated with increased TRAIL-mediated toxicity in A549 cells in vitro.

Methods

Cell proliferation and viability were determined by an automatic cell counter. Gene silencing was performed by introducing small interfering RNA into cells. Expression changes of cellular proteins were determined by western blot analysis. Apoptotic cell death was monitored by western blot analysis. Analysis of variance followed by the post-hoc Dunnett’s test was used to compare the data.

Results

EEDS treatment increased both mRNA and protein levels of DR4 and DR5 in the TRAIL refractory A549 cells. Co-treatment of A549 cells with sub-lethal dose of EEDS and recombinant TRAIL increased the apoptotic cell death. Upregulation of DR5 by EEDS was mediated by an endoplasmic reticulum stress-induced transcription factor, CCAAT/enhancer-binding protein homologous protein (CHOP), and knockdown of CHOP expression inhibited EEDS-induced DR5 upregulation and abolished the EEDS-associated increase in TRAIL toxicity in A549 cells.

Conclusions

EEDS can sensitize A549 cells to TRAIL cytotoxicity by upregulation of TRAIL death receptors. Our findings suggested that EEDS is a good initial herbal source for the development of an anticancer supplement for anticancer therapeutics associated with TRAIL.
Appendix
Available only for authorised users
Literature
1.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
2.
3.
go back to reference Feng Y, Wang N, Zhu M, Feng Y, Li H, Tsao S. Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Pat Food Nutr Agric. 2011;3:30–48.CrossRefPubMed Feng Y, Wang N, Zhu M, Feng Y, Li H, Tsao S. Recent progress on anticancer candidates in patents of herbal medicinal products. Recent Pat Food Nutr Agric. 2011;3:30–48.CrossRefPubMed
4.
go back to reference Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621–30.CrossRefPubMed Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 2008;26:3621–30.CrossRefPubMed
5.
go back to reference Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82.CrossRefPubMed Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–82.CrossRefPubMed
6.
go back to reference Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–90.CrossRefPubMed Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271:12687–90.CrossRefPubMed
7.
go back to reference Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013;19:685–94.CrossRefPubMed Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013;19:685–94.CrossRefPubMed
8.
go back to reference Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal. 2015;27:293–305.CrossRefPubMedPubMedCentral Lee DH, Sung KS, Bartlett DL, Kwon YT, Lee YJ. HSP90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells. Cell Signal. 2015;27:293–305.CrossRefPubMedPubMedCentral
9.
go back to reference Szliszka E, Sokol-Letowska A, Kucharska AZ, Jaworska D, Czuba ZP, Krol W. Ethanolic extract of Polish propolis: chemical composition and TRAIL-R2 death receptor targeting apoptotic activity against prostate cancer cells. Evid Based Complement Alternat Med. 2013;2013:757628.PubMedPubMedCentral Szliszka E, Sokol-Letowska A, Kucharska AZ, Jaworska D, Czuba ZP, Krol W. Ethanolic extract of Polish propolis: chemical composition and TRAIL-R2 death receptor targeting apoptotic activity against prostate cancer cells. Evid Based Complement Alternat Med. 2013;2013:757628.PubMedPubMedCentral
11.
go back to reference Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–62.CrossRefPubMedPubMedCentral Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest. 1999;104:155–62.CrossRefPubMedPubMedCentral
12.
go back to reference Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–63.CrossRefPubMed Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999;5:157–63.CrossRefPubMed
13.
go back to reference Han MH, Park C, Kwon TK, Kim GY, Kim WJ, Hong SH, et al. The histone deacetylase inhibitor trichostatin A sensitizes human renal carcinoma cells to TRAIL-induced apoptosis through down-regulation of c-FLIPL. Biomol Ther (Seoul). 2015;23:31–8.CrossRef Han MH, Park C, Kwon TK, Kim GY, Kim WJ, Hong SH, et al. The histone deacetylase inhibitor trichostatin A sensitizes human renal carcinoma cells to TRAIL-induced apoptosis through down-regulation of c-FLIPL. Biomol Ther (Seoul). 2015;23:31–8.CrossRef
14.
go back to reference Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release. 2011;154:93–102.CrossRefPubMed Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release. 2011;154:93–102.CrossRefPubMed
15.
go back to reference Wang H, Davis JS, Wu X. Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity. Mol Cancer Ther. 2014;13:643–50.CrossRefPubMed Wang H, Davis JS, Wu X. Immunoglobulin Fc domain fusion to TRAIL significantly prolongs its plasma half-life and enhances its antitumor activity. Mol Cancer Ther. 2014;13:643–50.CrossRefPubMed
16.
go back to reference Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, et al. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with bortezomib. J Control Release. 2014;192:157–66.CrossRefPubMed Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E, et al. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with bortezomib. J Control Release. 2014;192:157–66.CrossRefPubMed
17.
go back to reference Kobayashi E, Kishi H, Ozawa T, Hamana H, Nakagawa H, Jin A, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Biophys Res Commun. 2014;453:798–803.CrossRefPubMed Kobayashi E, Kishi H, Ozawa T, Hamana H, Nakagawa H, Jin A, et al. A chimeric antigen receptor for TRAIL-receptor 1 induces apoptosis in various types of tumor cells. Biochem Biophys Res Commun. 2014;453:798–803.CrossRefPubMed
18.
go back to reference Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene. 2003;22:5427–35.CrossRefPubMed Frese S, Pirnia F, Miescher D, Krajewski S, Borner MM, Reed JC, et al. PG490-mediated sensitization of lung cancer cells to Apo2L/TRAIL-induced apoptosis requires activation of ERK2. Oncogene. 2003;22:5427–35.CrossRefPubMed
19.
go back to reference Jung KJ, Min KJ, Bae JH, Kwon TK. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells. Oncotarget. 2015;6:1556–68.CrossRefPubMedPubMedCentral Jung KJ, Min KJ, Bae JH, Kwon TK. Carnosic acid sensitized TRAIL-mediated apoptosis through down-regulation of c-FLIP and Bcl-2 expression at the post translational levels and CHOP-dependent up-regulation of DR5, Bim, and PUMA expression in human carcinoma caki cells. Oncotarget. 2015;6:1556–68.CrossRefPubMedPubMedCentral
20.
go back to reference Shi YL, Feng S, Chen W, Hua ZC, Bian JJ, Yin W. Mitochondrial inhibitor sensitizes non-small-cell lung carcinoma cells to TRAIL-induced apoptosis by reactive oxygen species and Bcl-XL/p53-mediated amplification mechanisms. Cell Death Dis. 2014;5, e1579.CrossRefPubMedPubMedCentral Shi YL, Feng S, Chen W, Hua ZC, Bian JJ, Yin W. Mitochondrial inhibitor sensitizes non-small-cell lung carcinoma cells to TRAIL-induced apoptosis by reactive oxygen species and Bcl-XL/p53-mediated amplification mechanisms. Cell Death Dis. 2014;5, e1579.CrossRefPubMedPubMedCentral
21.
go back to reference Ohtsuki T, Kikuchi H, Koyano T, Kowithayakorn T, Sakai T, Ishibashi M. Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis. Bioorg Med Chem. 2009;17:6748–54.CrossRefPubMed Ohtsuki T, Kikuchi H, Koyano T, Kowithayakorn T, Sakai T, Ishibashi M. Death receptor 5 promoter-enhancing compounds isolated from Catimbium speciosum and their enhancement effect on TRAIL-induced apoptosis. Bioorg Med Chem. 2009;17:6748–54.CrossRefPubMed
22.
go back to reference Han SJ, Ahn TK, Choi HS, Shin JN, Piya S, Kim TH. TRAIL-induced cell death and caspase-8 activation are inhibited by cisplatin but not carboplatin. J Gynecol Oncol. 2009;20:113–6.CrossRefPubMedPubMedCentral Han SJ, Ahn TK, Choi HS, Shin JN, Piya S, Kim TH. TRAIL-induced cell death and caspase-8 activation are inhibited by cisplatin but not carboplatin. J Gynecol Oncol. 2009;20:113–6.CrossRefPubMedPubMedCentral
23.
go back to reference Lee DH, Rhee JG, Lee YJ. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol. 2009;157:1189–202.CrossRefPubMedPubMedCentral Lee DH, Rhee JG, Lee YJ. Reactive oxygen species up-regulate p53 and Puma; a possible mechanism for apoptosis during combined treatment with TRAIL and wogonin. Br J Pharmacol. 2009;157:1189–202.CrossRefPubMedPubMedCentral
24.
go back to reference Kim BY, Lee J, Park SJ, Bang OS, Kim NS. Gene expression profile of the A549 human non-small cell lung carcinoma cell line following treatment with the seeds of Descurainia sophia, a potential anticancer drug. Evid Based Complement Alternat Med. 2013;2013:584604.PubMedPubMedCentral Kim BY, Lee J, Park SJ, Bang OS, Kim NS. Gene expression profile of the A549 human non-small cell lung carcinoma cell line following treatment with the seeds of Descurainia sophia, a potential anticancer drug. Evid Based Complement Alternat Med. 2013;2013:584604.PubMedPubMedCentral
25.
go back to reference Jin CY, Park C, Hwang HJ, Kim GY, Choi BT, Kim WJ, et al. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol Nutr Food Res. 2011;55:300–9.CrossRefPubMed Jin CY, Park C, Hwang HJ, Kim GY, Choi BT, Kim WJ, et al. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol Nutr Food Res. 2011;55:300–9.CrossRefPubMed
26.
go back to reference Zhang X, Zhao J, Zhu W, Gou H, Cao D, Yang Y, et al. Synergistic effect of subtoxic-dose cisplatin and TRAIL to mediate apoptosis by down-regulating decoy receptor 2 and up-regulating caspase-8, caspase-9 and Bax expression on NCI-H460 and A549 Cells. Iran J Basic Med Sci. 2013;16:710–8.PubMedPubMedCentral Zhang X, Zhao J, Zhu W, Gou H, Cao D, Yang Y, et al. Synergistic effect of subtoxic-dose cisplatin and TRAIL to mediate apoptosis by down-regulating decoy receptor 2 and up-regulating caspase-8, caspase-9 and Bax expression on NCI-H460 and A549 Cells. Iran J Basic Med Sci. 2013;16:710–8.PubMedPubMedCentral
27.
go back to reference Yi JM, Park JS, Oh SM, Lee J, Kim J, Oh DS, et al. Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo. BMC Complement Altern Med. 2012;12:243.CrossRefPubMedPubMedCentral Yi JM, Park JS, Oh SM, Lee J, Kim J, Oh DS, et al. Ethanol extract of Gleditsia sinensis thorn suppresses angiogenesis in vitro and in vivo. BMC Complement Altern Med. 2012;12:243.CrossRefPubMedPubMedCentral
28.
go back to reference Yi L, Zongyuan Y, Cheng G, Lingyun Z, Guilian Y, Wei G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 2014;105:520–7.CrossRefPubMedPubMedCentral Yi L, Zongyuan Y, Cheng G, Lingyun Z, Guilian Y, Wei G. Quercetin enhances apoptotic effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in ovarian cancer cells through reactive oxygen species (ROS) mediated CCAAT enhancer-binding protein homologous protein (CHOP)-death receptor 5 pathway. Cancer Sci. 2014;105:520–7.CrossRefPubMedPubMedCentral
29.
go back to reference Lee JY, Jung KH, Morgan MJ, Kang YR, Lee HS, Koo GB, et al. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther. 2013;12:274–85.CrossRefPubMed Lee JY, Jung KH, Morgan MJ, Kang YR, Lee HS, Koo GB, et al. Sensitization of TRAIL-induced cell death by 20(S)-ginsenoside Rg3 via CHOP-mediated DR5 upregulation in human hepatocellular carcinoma cells. Mol Cancer Ther. 2013;12:274–85.CrossRefPubMed
30.
go back to reference Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228–37.CrossRefPubMed Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther. 2005;12:228–37.CrossRefPubMed
31.
go back to reference Golalikhani M, Khodaiyan F, Khosravi A. Response surface optimization of mucilage aqueous extraction from flixweed (Descurainia sophia) seeds. Int J Biol Macromol. 2014;70:444–9.CrossRefPubMed Golalikhani M, Khodaiyan F, Khosravi A. Response surface optimization of mucilage aqueous extraction from flixweed (Descurainia sophia) seeds. Int J Biol Macromol. 2014;70:444–9.CrossRefPubMed
32.
go back to reference Amiri MS, Joharchi MR, Taghavizadehyazdi ME. Ethno-medicinal plants used to cure jaundice by traditional healers of mashhad, iran. Iran J Pharm Res. 2014;13:157–62.PubMedPubMedCentral Amiri MS, Joharchi MR, Taghavizadehyazdi ME. Ethno-medicinal plants used to cure jaundice by traditional healers of mashhad, iran. Iran J Pharm Res. 2014;13:157–62.PubMedPubMedCentral
33.
go back to reference Li J, Liu X, Dong F, Xu J, Zheng Y, Shan W. Determination of the volatile composition in essential oil of Descurainia sophia (L.) Webb ex Prantl (Flixweed) by gas chromatography/mass spectrometry (GC/MS). Molecules. 2010;151:233–40.CrossRef Li J, Liu X, Dong F, Xu J, Zheng Y, Shan W. Determination of the volatile composition in essential oil of Descurainia sophia (L.) Webb ex Prantl (Flixweed) by gas chromatography/mass spectrometry (GC/MS). Molecules. 2010;151:233–40.CrossRef
34.
go back to reference Sun K, Li X, Liu JM, Wang JH, Li W, Sha Y. A novel sulphur glycoside from the seeds of Descurainia sophia (L.). J Asian Nat Prod Res. 2005;7:853–6.CrossRefPubMed Sun K, Li X, Liu JM, Wang JH, Li W, Sha Y. A novel sulphur glycoside from the seeds of Descurainia sophia (L.). J Asian Nat Prod Res. 2005;7:853–6.CrossRefPubMed
35.
go back to reference Lee YJ, Kim NS, Kim H, Yi JM, Oh SM, Bang OS, et al. Cytotoxic and anti-inflammatory constituents from the seeds of Descurainia sophia. Arch Pharm Res. 2013;36:536–41.CrossRefPubMed Lee YJ, Kim NS, Kim H, Yi JM, Oh SM, Bang OS, et al. Cytotoxic and anti-inflammatory constituents from the seeds of Descurainia sophia. Arch Pharm Res. 2013;36:536–41.CrossRefPubMed
36.
go back to reference Sun K, Li X, Li W, Wang J, Liu J, Sha Y. Two new lactones and one new aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one from Descurainia sophia. Chem Pharm Bull (Tokyo). 2004;52:1483–6.CrossRef Sun K, Li X, Li W, Wang J, Liu J, Sha Y. Two new lactones and one new aryl-8-oxa-bicyclo[3,2,1]oct-3-en-2-one from Descurainia sophia. Chem Pharm Bull (Tokyo). 2004;52:1483–6.CrossRef
37.
go back to reference Bekker NP, Ul’chenko NT, Glushenkova AI. Lipids from Descurainia sophia seeds. Chem Nat Compd. 2005;41:346–7.CrossRef Bekker NP, Ul’chenko NT, Glushenkova AI. Lipids from Descurainia sophia seeds. Chem Nat Compd. 2005;41:346–7.CrossRef
38.
go back to reference Sun K, Li X, Li W, Liu JM, Wang JH, Sha Y. A new nor-lignan from the seeds of Descurainia sophia. Nat Prod Res. 2006;20:519–22.CrossRefPubMed Sun K, Li X, Li W, Liu JM, Wang JH, Sha Y. A new nor-lignan from the seeds of Descurainia sophia. Nat Prod Res. 2006;20:519–22.CrossRefPubMed
39.
go back to reference Mohamed NH, Mahrous AE. Chemical constituents of Descurainia sophia L. and its biological activity. Rec Nat Prod. 2009;3:58–67. Mohamed NH, Mahrous AE. Chemical constituents of Descurainia sophia L. and its biological activity. Rec Nat Prod. 2009;3:58–67.
40.
go back to reference Khan M, Wang N. Descurainia sophia (L.): a weed with multiple medicinal uses. Punjab Univ J Zool. 2012;27:45–51. Khan M, Wang N. Descurainia sophia (L.): a weed with multiple medicinal uses. Punjab Univ J Zool. 2012;27:45–51.
41.
go back to reference Tse AK, Chow KY, Cao HH, Cheng CY, Kwan HY, Yu H, et al. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2013;288:29923–33.CrossRefPubMedPubMedCentral Tse AK, Chow KY, Cao HH, Cheng CY, Kwan HY, Yu H, et al. The herbal compound cryptotanshinone restores sensitivity in cancer cells that are resistant to the tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem. 2013;288:29923–33.CrossRefPubMedPubMedCentral
42.
go back to reference Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004;279:45495–502.CrossRefPubMed Yamaguchi H, Wang HG. CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem. 2004;279:45495–502.CrossRefPubMed
43.
go back to reference Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005;65:5662–7.CrossRefPubMed Yoshida T, Shiraishi T, Nakata S, Horinaka M, Wakada M, Mizutani Y, et al. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein. Cancer Res. 2005;65:5662–7.CrossRefPubMed
44.
go back to reference Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T, et al. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Int J Oncol. 2012;40:1483–91.PubMed Fujiwara J, Sowa Y, Horinaka M, Koyama M, Wakada M, Miki T, et al. The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells. Int J Oncol. 2012;40:1483–91.PubMed
45.
go back to reference Jung EM, Park JW, Choi KS, Park JW, Lee HIL, Lee KS, et al. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis. 2006;27:2008–17.CrossRefPubMed Jung EM, Park JW, Choi KS, Park JW, Lee HIL, Lee KS, et al. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis. 2006;27:2008–17.CrossRefPubMed
Metadata
Title
Ethanolic extract of Descurainia sophia seeds sensitizes A549 human lung cancer cells to TRAIL cytotoxicity by upregulating death receptors
Authors
Jong-Shik Park
Chae Jun Lim
Ok-Sun Bang
No Soo Kim
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Complementary Medicine and Therapies / Issue 1/2016
Electronic ISSN: 2662-7671
DOI
https://doi.org/10.1186/s12906-016-1094-0

Other articles of this Issue 1/2016

BMC Complementary Medicine and Therapies 1/2016 Go to the issue